These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 22586352)
1. New routes to old places: PIK3R1 and PIK3R2 join PIK3CA and PTEN as endometrial cancer genes. Herrero-Gonzalez S; Di Cristofano A Cancer Discov; 2011 Jul; 1(2):106-7. PubMed ID: 22586352 [TBL] [Abstract][Full Text] [Related]
2. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976 [TBL] [Abstract][Full Text] [Related]
3. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Urick ME; Rudd ML; Godwin AK; Sgroi D; Merino M; Bell DW Cancer Res; 2011 Jun; 71(12):4061-7. PubMed ID: 21478295 [TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826 [TBL] [Abstract][Full Text] [Related]
5. The Opposing Roles of PIK3R1/p85α and PIK3R2/p85β in Cancer. Vallejo-Díaz J; Chagoyen M; Olazabal-Morán M; González-García A; Carrera AC Trends Cancer; 2019 Apr; 5(4):233-244. PubMed ID: 30961830 [TBL] [Abstract][Full Text] [Related]
6. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Oda K; Stokoe D; Taketani Y; McCormick F Cancer Res; 2005 Dec; 65(23):10669-73. PubMed ID: 16322209 [TBL] [Abstract][Full Text] [Related]
7. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Velasco A; Bussaglia E; Pallares J; Dolcet X; Llobet D; Encinas M; Llecha N; Palacios J; Prat J; Matias-Guiu X Hum Pathol; 2006 Nov; 37(11):1465-72. PubMed ID: 16949921 [TBL] [Abstract][Full Text] [Related]
8. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases. Dornan GL; Burke JE Front Immunol; 2018; 9():575. PubMed ID: 29616047 [TBL] [Abstract][Full Text] [Related]
9. Class I Phosphoinositide 3-Kinase Mazloumi Gavgani F; Smith Arnesen V; Jacobsen RG; Krakstad C; Hoivik EA; Lewis AE Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544563 [TBL] [Abstract][Full Text] [Related]
10. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979 [TBL] [Abstract][Full Text] [Related]
11. The double life of p85. Costa C; Engelman JA Cancer Cell; 2014 Oct; 26(4):445-7. PubMed ID: 25314071 [TBL] [Abstract][Full Text] [Related]
12. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Westin SN; Ju Z; Broaddus RR; Krakstad C; Li J; Pal N; Lu KH; Coleman RL; Hennessy BT; Klempner SJ; Werner HM; Salvesen HB; Cantley LC; Mills GB; Myers AP Mol Oncol; 2015 Oct; 9(8):1694-703. PubMed ID: 26045339 [TBL] [Abstract][Full Text] [Related]
14. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572 [TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001 [TBL] [Abstract][Full Text] [Related]
16. Pan-cancer analysis on the role of PIK3R1 and PIK3R2 in human tumors. Liu Y; Wang D; Li Z; Li X; Jin M; Jia N; Cui X; Hu G; Tang T; Yu Q Sci Rep; 2022 Apr; 12(1):5924. PubMed ID: 35395865 [TBL] [Abstract][Full Text] [Related]
17. Expression status and mutational analysis of the PTEN and P13K subunit genes in ovarian granulosa cell tumors. Bittinger S; Alexiadis M; Fuller PJ Int J Gynecol Cancer; 2009 Apr; 19(3):339-42. PubMed ID: 19407556 [TBL] [Abstract][Full Text] [Related]
18. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Chen L; Yang L; Yao L; Kuang XY; Zuo WJ; Li S; Qiao F; Liu YR; Cao ZG; Zhou SL; Zhou XY; Yang WT; Shi JX; Huang W; Hu X; Shao ZM Nat Commun; 2018 Apr; 9(1):1357. PubMed ID: 29636477 [TBL] [Abstract][Full Text] [Related]
19. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma]. Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203 [TBL] [Abstract][Full Text] [Related]
20. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Rudd ML; Price JC; Fogoros S; Godwin AK; Sgroi DC; Merino MJ; Bell DW Clin Cancer Res; 2011 Mar; 17(6):1331-40. PubMed ID: 21266528 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]